CytomX Therapeutics (CTMX) Gains from Sales and Divestitures (2022 - 2025)
Historic Gains from Sales and Divestitures for CytomX Therapeutics (CTMX) over the last 4 years, with Q3 2025 value amounting to $527238.0.
- CytomX Therapeutics' Gains from Sales and Divestitures fell 2541.79% to $527238.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $527238.0, marking a year-over-year decrease of 2541.79%. This contributed to the annual value of $733201.0 for FY2024, which is 6689.11% up from last year.
- As of Q3 2025, CytomX Therapeutics' Gains from Sales and Divestitures stood at $527238.0, which was down 2541.79% from $527238.0 recorded in Q2 2025.
- Over the past 5 years, CytomX Therapeutics' Gains from Sales and Divestitures peaked at $733201.0 during Q4 2024, and registered a low of $110892.0 during Q1 2023.
- Its 4-year average for Gains from Sales and Divestitures is $462613.8, with a median of $521404.0 in 2025.
- As far as peak fluctuations go, CytomX Therapeutics' Gains from Sales and Divestitures surged by 53748.78% in 2024, and later tumbled by 2624.32% in 2025.
- CytomX Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $193750.0 in 2022, then skyrocketed by 126.75% to $439329.0 in 2023, then skyrocketed by 66.89% to $733201.0 in 2024, then dropped by 28.09% to $527238.0 in 2025.
- Its last three reported values are $527238.0 in Q3 2025, $527238.0 for Q2 2025, and $521404.0 during Q1 2025.